Clinical and epidemiological characteristics among probable and confirmed patients with
mpox in Sierra Leone reported from January to May 2025

Jia B Kangbai[1#], Emmanuel Saidu[2], Ibrahim K. Foday[2], Emmanuel S. Kamanda[2], Michaella
Jaba[3], Christopher M Ruis[4], Lorenzo Subissi[4], Megan Halbrook[5], Sydney Merritt[5], Jean-Claude
Makangara-Cigolo[6,7], Eddy Kinganda-Lusamaki[8,9,10], Laurens Liesenborghs[11], Isaac I Bogoch[12],
Souradet Y Shaw[13], Placide Mbala-Kingebeni[6,8], Anne W Rimoin[5#], Jason Kindrachuk[3,11#]

Affiliations

[1]Department of Public Health, Njala University, Bo, Sierra Leone

[2]Department of Biological Sciences, Njala University, Bo, Sierra Leone

[3]Department of Medical Microbiology & Infectious Diseases, University of Manitoba,
Winnipeg, Manitoba, Canada

[4]World Health Organization, Geneva, Switzerland

[5]Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University
of California, Los Angeles, California, USA

[6]Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the
Congo

[7]Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland

[8]Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de
Kinshasa, Université de Kinshasa

[9]Rodolphe Merieux INRB-Goma Laboratory, Goma, Democratic Republic of the Congo

[10]TransVIHMI (Recherches Translationnelles sur le VIH et les Maladies Infectieuses), Université
de Montpellier, Institut de Recherche pour le Développement (IRD), Institut National de Santé et
de Recherche Médicale (INSERM), Montpellier, France

[11]Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; Department
of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium

[12]Divisions of Infectious Diseases and General Internal Medicine, Toronto General Hospital,
University Health Network, Toronto, Ontario, Canada

[13]Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

[11]Department of Internal Medicine, University of Manitoba, Canada

[#]**Corresponding authors:** Jia B Kangbai (jkangbai@tulane.edu); Anne W Rimoin
(arimoin@ucla.edu); Jason Kindrachuk (Jason.Kindrachuk@umanitoba.ca)

ABSTRACT

We analysed available mpox cases reports in Sierra Leone from January to May 2025 following

a historic increase in mpox cases across multiple urban and rural regions in the country. Here, we

assessed demographic and clinical data from 161 case reports. Mpox case reports were primarily

from Bo (60/124; 48.4%) and Freetown (48/124; 38.7%). Most case reports were from male

patients (55.3%) as compared to females (44.7%), with an overall median age of 25 years (IQR

21-32). The median age was higher among males (30 years; IQR 23-39) then females (24 years;

IQR 20-27). Rash, fever, headache, and lesions were reported for all patients where data was

reported. Muscle pain, lymphadenopathy, sore throat, and cough were reported less commonly.

Age- and sex-specific interventions, as well as community engagement that includes historically

stigmatized groups are critical for mpox containment and mitigation measures in Sierra Leone.

Keywords: mpox; mpox virus; Sierra Leone; demographics; outbreak ; epidemiology; clinical

characteristics

INTRODUCTION

Mpox is an emerging zoonotic viral disease caused by mpox virus (also known as monkeypox virus; MPXV) endemic in tropical forest regions of Central and Western Africa [1, 2]. Human mpox was first identified in the Democratic Republic of the Congo (DRC) in 1970 with subsequent infections identified in multiple West African countries from 1970-1971 [3-5]. Historically, MPXV was described by two genetically, clinically, and geographically distinct clades, Clade I and Clade II, which are endemic in tropical, forested regions of Central Africa and Western Africa, respectively [1, 2]. Clades I and II have been subdivided into two subclades – a and b. The emergence of subclades Ib and IIb have been associated altered clinical and epidemiological characteristics, extensive APOBEC3 mutations, and rapid geographic expansion due to sustained human-to-human transmissions, including within dense sexual networks [6-8]. Rapid global expansion of Clade IIb MPXV in 2022 resulted in >91,000 confirmed infections in non-endemic regions and the declaration of the first public health emergency of international concern for mpox by the World Health Organization (WHO) [7, 9]. A second mpox PHEIC associated with Clade I MPXV was declared in 2024 and is currently ongoing [10].

Prior to 2022, knowledge regarding mpox morbidity and mortality were largely driven based on data from Clade I MPXV infections in Central Africa. Historically, the Democratic Republic of the Congo has faced the greatest public health impacts from mpox among all endemic and non-endemic regions, with the highest morbidity and mortality found among children <5 years [11, 12]. The extent of Clade II MPXV circulation among regions in West Africa is largely unknown though the circulation of subclades IIa and IIb correspond to regions east and west of the Dahomey Gap, respectively [13]. In regions where Clade II MPXV is considered endemic, there were a total of 302 reported mpox cases from 1970-2021 [14]. Most data on Clade II mpox morbidity and mortality in West Africa have been based on observations from reports following mpox re-emergence in Nigeria, which has included 270 mpox cases since 2017 [15, 16]. Of note, cases were overrepresented among young adults rather than children, and predominantly in males, including suspected sexual contacts as well as the linkage between more severe outcomes with uncontrolled HIV

Rapid geographic expansion of Clade IIb MPXV in 2022 among non-endemic regions of the

globe typified by atypical clinical presentation compared to historical data [9, 17, 18]. Clade IIb

infections during the first mpox PHEIC were concentrated within dense sexual networks and

primarily among males that identified as gay, bisexual, and other men who have sex with men

(gbMSM) [19].

The historic burden of human mpox in Sierra Leone has been very low with only three reported

infections from 1970 through to 2021 and no weekly case totals from 2022 through to the late

December 2024 [4, 14, 19-21]. No mpox cases were identified in Sierra Leone between 1970 and

2014 with single cases identified in 2014 and 2017. However, a serological investigation

undertaken in the Kenema District, Sierra Leone, strong IgG seropositivity among 1.3% of

participants were born after the cessation of smallpox vaccination [22]. Positive IgM titers were

also identified in six participants, with four being born after smallpox vaccination cessation.

These data suggested that while infrequent, cryptic orthopoxvirus exposures were occurring in

the absence of reported infections. However, there has been a rapid escalation in mpox cases in

Sierra Leone starting in January 2025 with 3011 confirmed mpox cases reported from to 23 May

2025. Concerningly, cases have been highly concentrated in the capital of Freetown (Pop.

~1.4M). Given the limited historical data for mpox burdens or clinical descriptions in West

Africa, the increase burden of the disease within Sierra Leone, and the potential for further

regional expansion, we sought to investigate clinical and epidemiological characteristics

associated with this outbreak.

MATERIALS AND METHODS

In this retrospective observational study, we analyzed 103 PCR-confirmed mpox cases reported

between January 2025 and April 20, 2025, from multiple sample collection sites across Sierra

Leone. We analysed national mpox testing and demographic data from anonymized data records

provided to us directly from healthcare facilities in Sierra Leone. During the study period, swab

samples from skin lesions were obtained from individuals presenting with signs and symptoms

consistent with mpox at various healthcare facilities nationwide. These samples were

subsequently transported to the capital, Freetown, for mpox testing at one of three laboratories:

Jui Hospital Laboratory, 34 Military Hospital Laboratory, or the Central Public Health Reference

Laboratory in Lakka. For this investigation, Freetown case reports came from Connaught

Hospital and Jui Hospital, which served as the main testing site from January to March, 2025.

Additional mpox patients case reports from other districts were also provided by Jui Hospital.

Mpox testing began in Kono in the third week of May 2025.

Institutional Review and Ethical Clearance

The Sierra Leone Ethics and Scientific Review Committee (SLERC No. 010/05/2025) and the

Health Research Ethics Board at the University of Manitoba, Canada (Opinion No. HS25837)

approved this study. We were waived from obtaining informed consent from mpox patients on

confidentiality purpose because we were analyzing facility-based aggregated medical records, as

well as anonymized patient data.

RESULTS

Case investigation from the earliest confirmed mpox patient preceding the 2025 mpox

outbreak in Sierra Leone

The earliest accessible mpox case report preceding the ongoing outbreak in Sierra Leone

involved a male patient aged between 26 and 35 years, who also disclosed as a person living with

HIV. He had no history of international travel. In December 2024, he traveled to Lungi, where he

reported unprotected sexual intercourse with a sex worker. Symptoms began the following day,

including headache, fever, progressive weakness, followed by the development of a rash and

lymphadenopathy. The patient also reported consuming cooked wild game, including goat,

sheep, and nonhuman primates.

Initially suspected to have malaria, he received treatment from a local Community Health

Worker in Lungi. However, with no improvement in symptoms, he subsequently sought

traditional remedies. The patient stated that none of his close contacts had been diagnosed with

mpox.

Demographics of probable and confirmed mpox patients from January to May 2025 in

Sierra Leone

From 01 January 2025 to 30 May 2025, there have been 3420 confirmed mpox cases in Sierra Leone, including 14 fatalities (CFR 0.46%). Of these, 2800 cases (81.9 %) have been reported from the Freetown area, including both the Western Rural (695 cases) and Western Urban (2105 cases) regions. Of the 3420 confirmed mpox cases, we were able to access demographic information for 161 cases, which spanned the period of January 2025 to May 2025 (Figure 1). The majority of the available mpox patient data in this study was reported from Bo (60/124; 48.4%), followed by Freetown (48/124; 38.7%), which includes both Western Urban Area (43 cases) and Western Rural Area (5 cases). Additional regions included Moyamba, Port Loko, Tonkolili, Bombali, and Karene, each having <5 mpox patient case reports. One case report was from an unknown location. The earliest accessible mpox case report preceding the ongoing outbreak in Sierra Leone involved a male patient aged between 26 and 35 years, who also disclosed as a person living with HIV. He had no history of international travel. In December 2024, he traveled to Lungi, where he reported unprotected sexual intercourse with a sex worker. Symptoms began the following day, including headache, fever, progressive weakness, followed by the development of a rash and lymphadenopathy. The patient also reported consuming cooked wild game, including goat, sheep, and nonhuman primates. Initially suspected to have malaria, he received treatment from a local Community Health Worker in Lungi. However, with no improvement in symptoms, he subsequently sought traditional remedies. The patient stated that none of his close contacts had been diagnosed with mpox.

Age and sex demographics for all probable and confirmed mpox patients included in this investigation are presented in Table 1 and Figure 2. Among the cases, 89/161 identified as male (55.3%) and 72/161 identified as female (44.7%). The median age among the patients with mpox in this investigation was 25 (IQR 21-32) with a higher median age among males (30 years; IQR 23-39) then females (24 years; IQR 20-27). The highest proportions of patients were aged 16-25 years followed by those aged 26-35 years, and 36-49 years, respectively, and collectively comprised 135/161 (83.9%) of all patients included in this study. Cases among males ranged from two weeks-to-55 years and from 11 months-to-75 years for females. The highest proportion of cases within our data sets were females aged 16-25 years (26.7%) followed by males aged 26-35 years (18.0%). More than half of female patients with mpox in this study were 16-25 years (43/72; 59.7%). In contrast, the highest proportion of male mpox patients were aged 26-35 years

and comprised 29/89 (32.6%) of male patients. Two female mpox patients self-identified as

commercial sex workers when asked about occupation.

Reported clinical and demographic characteristics for confirmed and probable mpox

patients in Sierra Leone

Clinical symptom characteristics that were provided for all probable and PCR-confirmed patients

with mpox in this investigation are presented in Table 2. Rash, fever, headache, cutaneous

lesions, and generalized pain were reported among all patients, where symptom data was

available for analysis. Lymphadenopathy, muscle pain, sore throat, and cough were reported by

the majority of patients with decreasing frequency, respectively. However, all were reported by a

higher proportion of male patients as compared to female patients. When considering sex-

specific reporting, lymphadenopathy was reported by 87.1% of males as compared to 75.9% of

females and generalized muscle pain was reported by 75.7% and 66.7% of male and female

patients, respectively. Sore throat and cough were reported by 73.6% and 66.7% of male

patients, respectively. However, female patients reported these less frequently at 43.1% and

37.5%, respectively. The median times between symptom onset and reporting to a health facility

were 5 days and 2.5 days for male and female mpox patients, respectively, where health seeking

data was reported. However, this data was only available for 20 patients - 9/20 males and 11/20

females.

Demographics and clinical symptom data for hospitalized mpox patients in Sierra Leone

Among all confirmed and probable cases included in this investigation, 49 of 161 patients with

mpox (30.4%) were hospitalized. Specifically, 21 of 89 male patients (23.6%) and 28 of 72

female patients (38.9%) were hospitalized based on the available data. Clinical symptoms and

age distribution for hospitalized patients are detailed in Table 3. The median age of hospitalized

patients was higher for males (29 years; IQR 22-38) than females (24; IQR 21-29).

The highest proportion of hospitalized patients with mpox were aged 16 - 25 years (24/49;

49.0%), followed by those aged 26 - 35 years (9/49; 18.4%) and 36 - 49 years (8/49; 16.3%).

Three hospitalized patients were children under 15 years of age, with two of those under the age

of five. Among patients aged 16 - 25 years, the majority were female (18/24); 6/24 males in this
age demographic were hospitalized.

Clinical symptom data from hospitalized patients indicated that rash, fever, and generalized pain
were present in all. Lymphadenopathy was reported in 30 of 49 patients (73.2%), while sore
throat (21/49; 42.9%) and cough (20/49; 40.8%) were reported less frequently. Female patients
with mpox had higher rates of lymphadenopathy, sore throat, and cough compared to male
patients.

DISCUSSION

This investigation provides a detailed clinical and epidemiologic characterization of the 2025
mpox outbreak in Sierra Leone, representing the first comprehensive report of its kind during the
current epidemic. Between January and 23 May 2025, a total of 3,011 confirmed mpox cases
have been reported nationwide, with the majority originating from Freetown and its surrounding
regions. Recent genome sequencing data has identified the hMPXV-1 (A) lineage of Clade IIb
among 32 of 33 genomes sequenced in the analysis [23]. MPXV Despite the national scale of the
outbreak, detailed demographic and clinical data were only accessible for 161 patients, offering a
focused yet valuable lens into transmission patterns, symptomology, and healthcare-seeking
behaviors during the early stages of this epidemic. The demographic distribution revealed that
young adults, particularly those aged 16 - 35 years, represented the highest burden of disease,
accounting for over 83.9% of cases analyzed. This suggests the expansion of mpox cases within
Sierra Leone in 2025 is being driven by sustained human to human transmission. A significant
proportion of affected individuals were female patients aged 16 - 25 years, suggesting that this
demographic is playing a central role in the local transmission dynamics, potentially driven by
behavioral, occupational, or sociocultural factors.

Clinically, the presentation of mpox in this cohort was largely consistent with prior outbreak
reports from other regions, with universal reports of rash, fever, and generalized pain among
cases where symptom data was available. Notably, females appeared to seek care earlier than
males, with a shorter median time from symptom onset to presentation at a healthcare facility
(2.5 vs. 5 days), which may have implications for early detection and containment efforts.

Hospitalization data is also consistent with outbreaks from other regions; and in the context of under sampling and bias toward detecting the more severe cases coming to medical attention, this cohort had 32.2% of patients admitted, with a predominance of young adult females aged 16 - 25 years. All hospitalized patients experienced rash, fever, and generalized pain. While our data access did not include contact tracing data for individual patients, nor information on epidemiological linkages between mpox patients, the concentration of mpox cases within the densely populated capital of Freetown (pop. ~1.4M), is reminiscent of our recent observations of mpox expansion in Kinshasa, DRC, driven by human-to-human transmission [24, 25]. In both investigations, mpox patients included in our analyses included those who self-identified as commercial sex workers, providing further support for dense sexual networks as a focal point for mpox circulation and transmission. In addition, many hospitalized patients in this study had densely concentrated genital lesions providing further support for linkage of mpox transmission in Sierra Leone to sexual and intimate contacts. Recent increases in mpox cases outside of Freetown, including Bombali, Port Loko, Kono, Kenema, and Bo suggest that the mpox epidemic is expanding regionally. Whether these have been due to single or multiple introductions of mpox virus or whether these case increases are linked to sustained human-to-human transmission have yet to be determined. However, the demographic data in this report provide strong support for sustained human-to-human transmission within dense population networks. It is appreciated that the 161 case reports analyzed in this investigation only represent a small cross-section of the total patients that reported to healthcare facilities for testing and evaluation during this outbreak. Acquisition of additional case report data is ongoing; however, this remains an ongoing challenge given the rapid expansion of the outbreak across numerous locations in Sierra Leone.

This report highlights early clinical and epidemiological observations from the rapidly expanding mpox epidemic currently ongoing in Sierra Leone. Mpox cases totals in 2025 have vastly surpassed the cumulative total of all mpox cases in-country from 1970 through 2024 and is now the second highest cumulative total in West Africa surpassed only by Nigeria, with 3,771 suspected mpox cases reported from the re-emergence of mpox in 2017 through 2024 [26]. Containment and mitigation efforts, including vaccine deployment to frontline healthcare

workers and those at increased risk for infection, as well as increased community engagement to

at-risk populations and increased access to testing (and diagnostic infrastructure) are needed.

ACKNOWLEDGEMENTS

This work was funded by the Canadian Institutes of Health Research (Grant no. PJT-175098). a Tier 2 Canada Research Chair in the Molecular Pathogenesis of Emerging and Re-Emerging Viruses for J.K. provided by the Canadian Institutes of Health Research (Grant no. 950–231498); the International Mpox Research Consortium (IMReC), jointly funded by the Canadian Institutes of Health Research and International Development Research Centre (grant nos. MRR-184813); Department of Defense, Defense Threat Reduction Agency, Monkeypox Threat Reduction Network (HDTRA1-21-1-0040); USDA Non-Assistance Cooperative Agreement #20230048; Belgian Directorate-general Development Cooperation and Humanitarian Aid and the Research Foundation - Flanders (FWO, grant number G096222 N to L.L.); US NIAID/NIH grant number U01AI151799 through Center for Research in Emerging Infectious Disease-East and Central Africa (CREID-ECA).

REFERENCES

1. Okwor, T., et al., *A contemporary review of clade-specific virological differences in monkeypox viruses.* Clin Microbiol Infect, 2023. **29**(12): p. 1502-1507.
2. Van Dijck, C., et al., *Emergence of mpox in the post-smallpox era-a narrative review on mpox epidemiology.* Clin Microbiol Infect, 2023. **29**(12): p. 1487-1492.
3. Breman, J.G., et al., *Human monkeypox, 1970-79.* Bull World Health Organ, 1980. **58**(2): p. 165-82.
4. Foster, S.O., et al., *Human monkeypox.* Bull World Health Organ, 1972. **46**(5): p. 569-76.
5. Ladnyj, I.D., P. Ziegler, and E. Kima, *A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo.* Bull World Health Organ, 1972. **46**(5): p. 593-7.
6. Happi, C., et al., *Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus.* PLoS Biol, 2022. **20**(8): p. e3001769.
7. Ulaeto, D., et al., *New nomenclature for mpox (monkeypox) and monkeypox virus clades.* Lancet Infect Dis, 2023. **23**(3): p. 273-275.
8. Vakaniaki, E.H., et al., *Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo.* Nat Med, 2024. **30**(10): p. 2791-2795.
9. Thornhill, J.P., et al., *Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022.* N Engl J Med, 2022. **387**(8): p. 679-691.
10. WHO, *WHO Director-General declares mpox outbreak a public health emergency of international concern.* 2024, WHO.

11. McCollum, A.M. and I.K. Damon, *Human monkeypox.* Clin Infect Dis, 2014. **58**(2): p.
260-7.
12. Bangwen, E., et al., *Suspected and confirmed mpox cases in DR Congo: a retrospective*
analysis of national epidemiological and laboratory surveillance data, 2010-23. Lancet,
2025. **405**(10476): p. 408-419.
13. Nakazawa, Y., et al., *A phylogeographic investigation of African monkeypox.* Viruses,
2015. **7**(4): p. 2168-84.
14. Titanji, B.K., et al., *Monkeypox: A Contemporary Review for Healthcare Professionals.*
Open Forum Infect Dis, 2022. **9**(7): p. ofac310.
15. Ogoina, D., et al., *Clinical Course and Outcome of Human Monkeypox in Nigeria.* Clin
Infect Dis, 2020. **71**(8): p. e210-e214.
16. Yinka-Ogunleye, A., et al., *Outbreak of human monkeypox in Nigeria in 2017-18: a*
clinical and epidemiological report. Lancet Infect Dis, 2019. **19**(8): p. 872-879.
17. Mailhe, M., et al., *Clinical characteristics of ambulatory and hospitalised patients with*
monkeypox virus infection: an observational cohort study. Clin Microbiol Infect, 2022.
18. Tarin-Vicente, E.J., et al., *Clinical presentation and virological assessment of confirmed*
human monkeypox virus cases in Spain: a prospective observational cohort study.
Lancet, 2022. **400**(10353): p. 661-669.
19. WHO. *2022-24 Mpox Outbreak: Global Trends*. 2025 21 May 2025 [cited 2025 24 May
]; Available from: https://worldhealthorg.shinyapps.io/mpx_global/.
20. Reynolds, M.G., et al., *Human Monkeypox in Sierra Leone after 44-Year Absence of*
Reported Cases. Emerg Infect Dis, 2019. **25**(5): p. 1023-1025.
21. Ye, F., et al., *Molecular Evidence of Human Monkeypox Virus Infection, Sierra Leone.*
Emerg Infect Dis, 2019. **25**(6): p. 1220-1222.
22. Macneil, A., et al., *Serologic evidence of human orthopoxvirus infections in Sierra Leone.*
BMC Res Notes, 2011. **4**: p. 465.
23. Sahr F, G.D., Harding D, Sandi JD, , *Genomic epidemiology of Mpox virus in Sierra*
Leone. 2025: Virological.
24. Wawina-Bokalanga, T., et al., *Co-circulation of monkeypox virus subclades Ia and Ib in*
Kinshasa Province, Democratic Republic of the Congo, July to August 2024. Euro
Surveill, 2024. **29**(38).
25. Wawina-Bokalanga T, M.S., Kinganda-Lusamaki E, Jansen D, Halbrook M et al,
Epidemiology and Phylogenomic Characterization of Distinct 2023 and 2024 Mpox
outbreaks in Kinshasa, Democratic Republic of the Congo - Evidence for increasingly
sustained human-to-human transmission of subclade Ia. medRxiv, 2024.
26. NCDC, *UPDATE ON MPOX (MPX) IN NIGERIA*. 2023, Nigeria Centre for Disease
Control.

330 **TABLES**

331 **Table 1. Age and sex demographics for probable and confirmed mpox patients in Sierra**
332 **Leone (n = 161). Values presented as N (%).**

		Male	Female	Total
N		89 (55.3)	72 (44.7)	161
Age				
	Median (IQR)	30 (23-39)	24 (20-27)	25 (21-32)
	0-5	3 (1.9)	3 (1.9)	6 (3.7)
	6-15	4 (2.5)	2 (1.2)	6 (3.7)
	16-25	17 (10.6)	43 (26.7)	60 (37.3)
	26-35	29 (18.0)	16 (9.9)	45 (28.0)
	36-49	26 (16.2)	4 (2.5)	30 (18.6)
	50+	4 (2.5)	2 (1.2)	6 (3.7)
	Unknown	6 (3.7)	2 (1.2)	8 (5.0)

342 **Table 2: Mpox clinical symptoms data from available patient data for this investigation.**

343 Total column represents N for available symptom data. Percentages (in parentheses) represent

344 sex-specific proportions of symptoms reported where data was available.

	Males	**Females**	**Total**
N	89	72	161
Clinical Symptoms			
Rash	89 (100)	72 (100)	161 (100)
Fever	89 (100)	72 (100)	161 (100)
Headache	37 (100)	12 (100)	49 (100)
Muscle Pain	28 (75.7)	8 (66.7)	36 (73.5)
Lymphadenopathy	61 (87.1)	41 (75.9)	102 (82.3)
Sore Throat	53 (73.6)	31 (43.0)	84 (50.9)
Cough	48 (66.7)	27 (37.5)	75 (46.6)
Lesions	37 (100)	12 (100)	49 (100)
Generalized pain	33 (100)	40 (100)	73 (100)

345

346

347

348

349

350

351

352

353

354

Table 3: Clinical and demographic characteristics of hospitalized mpox patients in Sierra Leone from this investigation. Total column represents N for data available for mpox patients with known hospitalization status in this investigation. For age data, percentages (parentheses) represent the sex-specific proportion of patients as compared to all patients at each age stratification. For clinical symptom data, percentages (in parentheses) represent sex-specific proportions of reported clinical symptoms, where data was available.

	Males	Females	Total
N	21	28	49
Age			
Median (IQR)	29 (22-38)	24 (21-29)	24 (21-32)
0-5	2 (5.3)	1 (2.6)	3 (7.9)
6-15	0	1 (2.6)	1 (2.6)
16-25	6 (15.8)	18 (47.4)	24 (63.2)
26-35	5 (13.2)	4 (10.5)	9 (23.7)
36-49	5 (13.2)	3 (7.9)	8 (21.1)
50+	1 (2.6)	1 (2.6)	2 (5.3)
Unknown	2 (5.3)	0	2 (5.3)
Clinical Symptoms			
Rash	20 (100)	40 (100)	60 (100)
Fever	21 (100)	40 (100)	61 (100)
Lymphadenopathy	12 (63.2)	18 (81.8)	30 (73.2)
Sore Throat	8 (38.1)	13 (32.5)	21 (42.9)
Cough	8 (38.1)	12 (30.0)	20 (40.8)
Generalized pain	19 (100)	22 (100)	41 (100)

FIGURES

Figure 1: Geographic locations of probable and PCR-confirmed mpox patients from 2025 mpox infections in Sierra Leone included in this investigation (n=161).

Location	Cases
Bo	60
Bombali	3
Karene	1
Kono	37
Moyamba	4
Port Loko	4
Tonkolili	3
Western Area Rural	5
Western Area Urban	43
Unknown	1

383 **Figure 2. Age and sex demographics for probable and confirmed mpox cases in Sierra**

384 **Leone (n = 161).**